Author: admin

Red clover decreases significantly, depressive and anxiety symptoms associated with menopause.

|

Red clover decreases significantly, depressive and anxiety symptoms associated with menopause.

– in general, about 75 per cent of women peri- and post-menopausal are symptomatic

-Main symptoms associated with menopause: hot flashes, headache, irritability, depression, insomnia, vaginal dryness, decreased concentration, the libido and the smoothness of the skin, and Dyspareunia

Madrid, 2011-September menopause, due to its symptoms, has both medical and social impact. According to Dr. Peter Chedraui – gynecologist from the Institute for women’s health, Guayaquil, Ecuador, and co-author of the article “ Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts ”, published in Maturitas, in March, 2010 – “ medical relationship lies in the decrease in estrogen that, in the short term, increases the risk of menopausal symptoms, which in turn decreases the quality of life of women ” [1,2]. “ On the other hand – adds – can generate long-term effects, such as the increase in the risk of osteoporosis, cardiovascular, urogenital atrophy and Alzheimer’s disease ” [3].

As a result, social impact related to climatérica symptoms, peri-menopáusicas women both in the post-menopausal, is quite high, as many of its symptoms are directly reflected in their personal relationships and lifestyles. Irritability, hot flashes, insomnia, depression, dyspareunia, vaginal dryness, decreased concentration, decreased libido, decreased self-esteem, among others, many of the problems faced by 75% of menopausal women.

“ Thanks to recent published studies about the benefits of red clover (Trifolium pratense) we can say that, is achieved through the intake of adequate doses of extract derived from this plant, decrease after 90 days and significantly, depressive and anxiety symptoms. In addition, combine it with soy isoflavones could enhance treatment, taking into account the level of evidence to the specific approach to hot flashes ”, says Dr. Chedraui.

In this sense, Fitogyn ®, Casen Fleet, is the first and only drug in herbal medicine combined with red clover and soybeans has been effective and safe in the reduction of the climatérica symptoms, significantly reducing the frequency of hot flashes in menopausal women.

As for the future in the treatment of menopausal symptoms, Dr. Chedraui stresses that “ the key is to individualize treatment, using optimal doses that are beneficial and minimize the risks as well as to analyse in detail the risks that may appear. This predicts that there will be a trend toward natural alternatives or non-hormonal compounds, to improve the symptoms with less possible side effects ”.

If you need more practical and proven information about the most common gynaecological problems, enter women’s solutions.

–
Referencia:

[1] Chedraui P, FR Pérez-López, Mendoza M, Morales B, MA Martinez, Salinas AM, et to the. Severe menopausal symptoms in middle aged women are associated to female and male factors Arch Gynecol Obstet 2010; 281: 879-885.

[2] Chedraui P, JE Blümel, Baron G, Belzares E, Bencosme, street, et to the. Impaired quality of life among middle aged women: to Latin American multicentre study. Maturitas 2008; 61: 323-329.

[3] FR Perez-Lopez, Chedraui P, Gilbert JJ, Pérez-Roncero g. Cardiovascular risk in menopausal women and related co-morbid conditions prevalent: facing the post-Women ’ s Health Initiative was. Fertil Steril 2009; 64: 1171-1186.

Read More

Fuenlabrada obtained the accreditation of the Multiprofesional unit of Mental health.

|

Fuenlabrada obtained the accreditation of the Multiprofesional unit of Health Mental.

will be trained psychiatrists, psychologists and nurses.

Spain, 2011-September the Ministry of health has awarded the teaching Accreditation Unit teaching Multiprofesional of Mental health of the University Hospital of Fuenlabrada, which concretará in the formation of two residents per year in the specialty of Psychiatry, a resident for the year in the field of psychology and two residents per year in the specialty of nursing Mental health.

The recognition of the teaching capacity of the hospital has been preceded by the desire to give coherence to the care dispensed to the patient psychiatric hospital from the various welfare authorities and has required a coordination effort of all educational devices that previously existed in the geographical area corresponding to Fuenlabrada and Leganés.

Instituto José Germain de Leganés, with its unit of rehabilitation hospital of medium and long stay, its ambulatory treatment centre and Hospital day thereof, together with the center of attention to the dependent of the municipality of Fuenlabrada and the community therapy of disorders limit of the personality of the clinic St. Miguel-Hermanas Hospital of San Juan de Diosthey are part of the educational devices that make up the new unit teaching Multiprofesional of Mental health.

Teaching hospital

Fuenlabrada University Hospital opened in the year 2006, patients acute psychiatric hospitalization unit. Later came the integration of the Instituto José Germain of Leganes-dependent neighborhood Mental Health Center in this unit. The hospital, since the beginning of its operation, has carried out a policy of close cooperation and rapprochement of all the existing welfare resources dependent both Councils and the community of Madrid.

Hospital Universitario de Fuenlabrada has shown its vocation teaching since its inception as thus highlights it the teaching accreditation in 13 specialties that obtained in the year 2007, scarce three years of their commissioning. They are currently 25 educational units accredited, bringing to 123 the number of residents. The year 2010 it was a new milestone in the teaching career of the hospital with the incorporation of students of Medicine of the Universidad Rey Juan Carlos to start their training undergraduate.

Read More

Research on Down syndrome and Alzheimers disease continues its advance.

|

Research on Down syndrome and Alzheimer’s disease continues its advance.

21 September day world of Alzheimer’s.

-el Dr. Javier García Alba, Professor in the Department of evolutionary psychology and of education of the Faculty of education (UCM) points to the importance of having test for cognitive assessments of persons with Down’s syndrome

Madrid, 2011-September last and recent studies in the period 2009-2011 by different research teamssome of the own Foundation syndrome of Down from Madrid (FSDM), have led to a series of advances in knowledge of Alzheimer’s disease in people with Down syndrome.

As explained by Dr. García Alba, there are signs of presence of the neuropathology of from relatively early stage Alzheimer’s disease in Down syndrome. However, this does not mean that all people with Down Syndrome will necessarily present the disease clinic.

It has also clarified that it had noted that “ there is a greater number of people with Alzheimer’s disease affected Down syndrome and early onset ”. However, there are discrepancies in the percentages of people with Down syndrome suffer from this disease. These discrepancies are related to the possibility of issuing false diagnoses. In this sense, García Alba has pointed out that “ the cognitive impairment that can occur when some people do not always is due to the effects of Alzheimer’s disease, since there are other pathologies involving such impairment ”.

The conclusions drawn from recent studies include: the interest in creating evidence to make good Diagnostics and detect early stages of Alzheimer’s disease, as well as the line of genetic research to discover new drugs, with the effect of delaying the progression of the disease and mitigate its symptoms in cognitive impairment.

For its part, the Foundation syndrome of Down in Madrid (FSDM) maintains the support “ total ” in relation to the projects and studies carried out to advance research on Down syndrome.

The syndrome Madrid Down Foundation (FSDM) was established in 1989 as a not-for-profit entity whose mission is: promote, develop and promote all kinds of activities aimed at the full family, school, employment and social integration of persons with intellectual disabilities and Down syndrome in order to improve the quality of life of this group and their families.

Read More

Genetics, one of the keys to the prognosis of progression of osteoarthritis.

|

Genetics, one of the keys to the prognosis of progression of osteoarthritis.

World Congress of osteoarthritis (OARSI).

-Bioiberica leads the project Arthrosischip to predict the evolution of the osteoarthritis of knee with an analysis of saliva

-Francisco j. Blanco Garcia, rheumatologist complex Hospitalario Universitario A Coruña, has presented at the OARSI databases of research, with the collaboration of 32 hospital centres of all Spain

Barcelona, 2011-September the study of the genetics of arthritis offers new fields of research on the forecast and the progression of osteoarthritis of the knee. So this weekend in arthrosis OARSI World Congress, held in San Diego (California), in which Bioiberica has introduced the Arthrosischip to predict the evolution of arthritis from a saliva sample has been exposed.

Arthritis is a disease with a strong genetic component in its development and progression. On some problems of osteoarthritis, genetic inheritance reaches between 60% and 70% of cases. This evidence has laid the basis of the investigation led by Bioiberica and expounded by Dr. Francisco j. Blanco, rheumatologist of the complex Hospitalario Universitario A Coruña, in the World Congress of osteoarthritis.

Dr. Francisco j. Blanco explained that arthritis is a poligenética disease with multiple interactions between genes. He also mentioned that genetic material can be found in the nucleus of the condrocitos both mitochondria and that such genetic material plays an important role in the development of the disease. In this way, different mitochondrial DNA haplogroups may have different phenotypes artrósicos and
probability of progression.

On the basis of these claims is developing the project Arthrosischip, to create a tool that combines clinical and genetic data (DNA chip) allowing to predict the progression of primary osteoarthritis of the knee in patients previously diagnosed the disease and to customize your treatment as well as predict the risk of implantation of prosthesis in such patients. Based on the technology of DNA microarrays, Arthrosischip shall consist of a genetic analysis from a saliva sample that could identify those genetic mutations associated with the progression of arthritis that are significant and clinical data, basically, risk factors such as sexthe IMC or concomitant diseases such as diabetes. Dr. White also explained the design of the trial (multicenter retrospective) which is currently in the final stage of the recruitment of samples.

It is a study jointly developed between Bioiberica, company with more than 30 years of experience in health of joints and leader in chondroprotection, and Progenika, specialist in the design and development of tools for personalized medicine. In it, involved 32 hospital centres of all Spain.

The OARSI in Barcelona in April 2012

With Bioiberica as one of the major sponsors, the next edition of OARSI will take place in Barcelona in April. During these days will gather in the city more than one thousand of specialists from around the world, including rheumatologists, researchers, orthopaedic surgeons, radiologists, clinical and other stakeholders in the research of arthritis. However, this Congress has the most prestigious professionals dedicated to the treatment of arthritis to share progress and experiences in the investigation of this disease. Why Barcelona and Spain will become one week the world headquarters of arthritis.

Bioiberica Farma

Bioiberica Farma is the only Spanish laboratory specializing in research and development of effective drugs for the treatment of osteoarthritis. Specifically, specialises in chondroprotection, namely, prevention, diagnosis and treatment of cartilage, synovial membrane, and the subcondral bone injuries.

This expertise in the treatment of osteoarthritis has helped Bioiberica Farma occupies a leading position endorsed by numerous published clinical trials, research projects underway, the recognition of different societies scientific and medical, strict quality control chemical and biological production processes, the quality of their products and editing of publications specialised in chondroprotection.

Read More

There was an error deserializing the object of type System.String. Encountered unexpected character l.

|

“Lacer Farma” leads a research to prevent disease cerebrovascular.

-the study, conducted in collaboration with the Group Neurovascular research at the Cajal Institute of the CSIC, elaborates on the mechanisms of self-defense that launches the central nervous system diseases such as Alzheimer’s and stroke cerebrovascular

– ‘ Lacer Farma ’ working on a molecule with vasodilator action, proangiogénica and antiapoptótica

Barcelona, 2011-September LA419, discovered and patented molecule by ‘ Lacer Farma ’, specialist in the cardiovascular field, could have protective and repair effects against cerebrovascular diseases such as stroke and Alzheimer’s disease, according to the preliminary results of the study being carried out between the Department’s r & d Pharma of laboratories Lacer directed by DRA. Marisabel Mourelle and the research group of the Department of Molecular Neurobiology at the Cajal Institute of the CSIC, directed by the prestigious researcher Dr. Ricardo Martinez-Murillo. The purpose of the investigation, which began a year ago, is to identify new applications of this molecule with vasodilator action, pro-angiogenic (allows the formation of blood vessels from pre-existing vessels) and antiapoptótica (prevents cell death) to prevent Neurovascular diseases and mitigate its effects.

Both stroke and Alzheimer’s disease are two cerebrovascular disease serious each year reaching an important population group. The stroke is the leading cause of death among women in Spain, – affects one in every seven – and the second among the general population and every year suffer to 130,000 people, of which 8,000 die or are disabled, according to the national register of stroke drawn up by the Group of study of disease stroke of the Spanish Neurology Society (GEECV-SEN). The World Health Organization (who) data show that these diseases already represent the third cause of death in the Western world, the physical disability in adults first and the second of dementia. WHO estimates suggest that over the next 15 years the incidence of stroke in the world’s population will increase by 27%.

Investigations allow promising expectations on new applications of the LA419 molecule, whose effectiveness has been demonstrated in the treatment of cardiovascular diseases.

In the case of the stroke, the administration of the molecule could have a preventive effect against disease and act as therapeutic agent in their treatment. Thus established the first results of the study in laboratory, suggest that the administration of the molecule 15 minutes later stroke reduces significantly the volume of vascular edema, which would enable a very significant reduction of neurological sequelae disabling arising from the stroke. Tests carried out have shown that the molecule, which has antithrombotic properties and antiisquémicas (prevents the decrease of blood flow), does not alter the blood pressure, so it is emerging as a possible therapeutic agent in the treatment of stroke.

In relation to Alzheimer’s disease, a process hitherto incurable neurodegenerative disease, researchers are analysing the potential effects of the LA419 molecule on the ability of learning and memory in experimental disease model animals. Because of its recognized antioxidant properties, the molecule can trap and inactivate free radicals and other oxidizing substances that damage cell membranes and causing, in the case of neurons, brain aging. The research aims to determine the possibilities of therapeutic use of this product through preclinical studies that are underway. In Spain, Alzheimer’s disease affects between 650,000 and 800,000 people, according to the Alzheimer’s Foundation. The report submitted in July in the Alzheimer Association International Conference concludes, after cancer, Alzheimer’s is the disease most feared by the Spanish.

About

DRA. Marisabel Mourelle Mancini. PhD in pharmacology by the Centre for research and advanced studies of the National Polytechnic Institute of Mexico (CINVESTAV) and head of the Department’s r & d & innovation laboratories Lacer. It is creative in 16 patents of new chemical entities, such as pain relievers or new molecules with antidiabetic activity, among others. Author of hundreds of publications in international scientific journals ‘ Circulation ’, ‘ Hypertension ’ and ‘ Gastroenterology ’, has participated in numerous conferences in congresses and scientific forums.

Dr. Ricardo Martínez Murillo. Doctor of medicine from the Universidad Complutense de Madrid and neurobiologist. Head of the Neurovascular research group in the Department of Molecular Neurobiology, cellular and the development of the Higher Council of scientific research (CSIC) in the Cajal Institute. Its main lines of research revolve around processes Neuropathological as cerebral ischemia and Alzheimer’s disease. He is the author of hundreds of publications in international journals such as ‘ Neuroscience ’, ‘ Brain Research ’ or ‘ Journal of Neuroscience Research ’; He has directed more than 30 research projects and has participated in numerous conferences in congresses and scientific forums.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips